

## Microba, SYNLAB Extend & Expand Distribution

- In 2020, Microba entered into agreements with Europe's largest pathology company SYNLAB (ETR: SYAB) to pursue a multi-phased distribution strategy for Microba's microbiome testing technology throughout Europe
- Microba and SYNLAB have executed a major amendment to the master agreement to enable distribution expansion and an extended term to December 2028
- The agreement also provides a new framework for SYNLAB's affiliate countries to rapidly expand distribution across Europe and Latin America
- The expanded field includes sales Direct to Consumer as well as Healthcare Providers

**Microba Life Sciences Limited** (ASX: MAP) ("Microba") is pleased to announce a master agreement amendment has been entered into with SYNLAB International GmbH ("SYNLAB") (ETR: SYAB) to expand their field and extend the term of agreement to December 2028.

In 2020, Microba entered into a master agreement with SYNLAB International GmbH and an agreement with SYNLAB Diagnosticos Globales to deliver Microba's testing solution to Healthcare Providers in Spain, with an option to formalise distribution agreements across their affiliate organisations, which operate in 36 countries. The details of these agreements are disclosed in Microba's prospectus dated 11 February 2022.

With positive sales and customer feedback in Spain, SYNLAB has further activated their rights to pursue formal expansion into additional countries across Europe and Latin America.

Microba and SYNLAB have executed a major amendment to the master agreement to enable this distribution expansion including; a new agreement framework for SYNLAB countries; an extended distribution term to 31 December 2028, and an expanded field to include sales direct to Consumers as well as Healthcare Providers.

**Microba's Senior Vice President of Services, Mr Bernie Woodcroft** said, "SYNLAB is the largest European clinical laboratory and medical diagnostic services company by revenue and number of tests, servicing around 100 million patients annually. Although progress was delayed by COVID-19, we have now laid the groundwork in Spain providing a blueprint for SYNLAB to expand into key countries they operate in. This is an important step-change in the relationship as we double-down to take a leading position in microbiome testing across Europe and Latin America"

**Microba's Chief Executive Officer, Dr Luke Reid** said, "This amendment to the master agreement exemplifies SYNLAB's conviction and long-term commitment to our partnership. I am pleased to see this partnership formally advance to the next phase to expand access to Microba's testing across their territories."

*This announcement has been authorised for release by the Chairman and Chief Executive Officer.*

For further information, please contact:

**Dr Luke Reid**  
Chief Executive Officer  
E: Luke.Reid@microba.com

**Simon Hinsley**  
Investor / Media Relations  
E: simon@nwrcommunications.com.au  
T: +61 401 809 653

**About SYNLAB**

SYNLAB Group is the leader in medical diagnostic services and specialty testing in Europe. The Group offers a full range of innovative and reliable medical diagnostics to patients, practising doctors, hospitals and clinics, governments and corporates. SYNLAB operates in 36 countries across four continents and holds leading positions in most markets, regularly reinforcing the strength of its network through a proven acquisition strategy. Around 30,000 employees, including over 2,000 medical experts, contribute every day to the Group's worldwide success.

**About Microba Life Sciences Limited**

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

**For more information visit: [www.microba.com](http://www.microba.com)**

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.